SEC Form 4 · accession 0000908662-16-000406
ENANTA PHARMACEUTICALS INC · ENTA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yat Sun Or
Officer — Chief Scientific Officer
Period of report
Jan 19, 2016
Accepted (ET)
Jan 20, 2016 · 4:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001177648
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 19, 2016 | M | 13,921 | $2.5429 | A | 300,717 | D | |
| Common Stock | Jan 19, 2016 | M | 5,800 | $2.5429 | A | 306,517 | D | |
| Common Stock | Jan 19, 2016 | M | 23,201 | $2.5429 | A | 329,718 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $2.5429 | Jan 19, 2016 | M | 13,921 | D | — | Apr 15, 2021 | Common Stock | 13,921 | 0 | D |
| Stock Option (right to buy)F1 | $2.5429 | Jan 19, 2016 | M | 5,800 | D | — | Jun 17, 2021 | Common Stock | 5,800 | 0 | D |
| Stock Option (right to buy)F1 | $2.5429 | Jan 19, 2016 | M | 23,201 | D | — | Sep 23, 2021 | Common Stock | 23,201 | 0 | D |
Explanation of responses
- F1100% of the shares subject to the option are fully vested and exercisable.